Research Triangle Park, NC, February 9, 2017 – Fennec Pharmaceuticals, Inc. (TSX: FRX, OTCQB: FENCF), today announced that Rosty Raykov, CEO of Fennec, will present at the 19th BIO CEO & Investor Conference on Monday, February 13, 2017 at 1:30 PM ET at the Waldorf Astoria Hotel in New York City. The Fennec presentation will […]
Read More… from FENNEC TO PRESENT AT 19TH ANNUAL BIO CEO & INVESTOR CONFERENCE
Research Triangle Park, NC, December 1, 2016 – Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced The Lancet Oncology published the results from the Children’s Oncology Group, “Effects of Sodium Thiosulfate versus Observation […]
SIOPEL 6 Updated Interim Results Presented at the International Society of Pediatric Oncology (SIOP) -confirms no evidence of tumor protection and final audiometry results will be available in the fourth quarter of 2017 Research Triangle Park, NC, November 14, 2016 – Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF), a specialty pharmaceutical company focused on the […]
Read More… from FENNEC PROVIDES CORPORATE UPDATE AND ANNOUNCES THIRD QUARTER 2016 RESULTS
No difference in Event free Survival (EFS) and Overall Survival (OS) at 2 years for cisplatin alone vs cisplatin + STS with no evidence of tumor protection Final audiometry results will be available at the end of 2017 Research Triangle Park, NC, October 24, 2016 – Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF), a specialty […]
Research Triangle Park, NC, September 8, 2016 – Fennec Pharmaceuticals, Inc. (TSX: FRX, OTCQB: FENCF), today announced that Rosty Raykov, CEO of Fennec, will present at the Rodman & Renshaw 18th Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The Company will be presenting at 3:25 EDT on Tuesday, September 13, 2016. […]
SIOPEL 6 interim results presented in oral presentation at ASCO 2016 confirms no evidence of tumor protection and is consistent with previous updates. Initial hearing efficacy data are “encouraging” with final hearing results expected in H2 2017. Closing of $5.0 million financing by Essetifin SpA (formerly Sigma Tau Finanziaria SpA) provides sufficient reserves to complete […]
Read More… from FENNEC PROVIDES CORPORATE UPDATE AND ANNOUNCES SECOND QUARTER 2016 RESULTS
Research Triangle Park, NC, August 11, 2016 – Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, announced today the appointment of Marco Brughera, DVM, CEO and Global Head of Sigma Tau Rare Disease, to its […]
Read More… from FENNEC ANNOUNCES APPOINTMENT OF MARCO BRUGHERA TO THE BOARD OF DIRECTORS
Research Triangle Park, NC, July 6, 2016 – Fennec Pharmaceuticals, Inc. (TSX: FRX, OTCQB: FENCF), today announced that the Company will present at the Cantor Fitzgerald 2nd Annual Healthcare Conference in New York City at 10:45 AM EDT on Wednesday, July 13, 2016. The conference is being held at the Le Parker Meridian in New […]
Research Triangle Park, NC — (Marketwired) – June 8, 2016– Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF) today announced that the nominees listed in the management proxy circular dated May 9, 2016 (the “Circular”) for the Annual Meeting of Shareholders were elected as directors of the Company at the Annual Meeting of Shareholders held in […]
No difference in Event free Survival (EFS) and Overall Survival (OS) at 2 years for cisplatin vs cisplatin + STS with no evidence of tumor protection The interim results of the first 68 patients achieving centrally reviewed pure tone audiometry at or above 3.5 years of age were encouraging Research Triangle Park, NC, June 6, […]